OFFICE LEASE by and between Diamond Marina LLC, a California limited liability company, and Diamond Marina II LLC, a California limited liability company as Landlord and Allergen Research Corporation, a Delaware Corporation, as Tenant Brisbane,...Office Lease • July 6th, 2015 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LEASE is entered into as of February 23, 2015 (the “Effective Date”) by and between DIAMOND MARINA LLC, a California limited liability company, and DIAMOND MARINA II LLC, a California limited liability company (collectively “Landlord”), and Allergen Research Corporation, a Delaware Corporation (“Tenant”).
CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION SUPPLY AGREEMENTSupply Agreement • July 6th, 2015 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • Illinois
This Supply Agreement (the “Agreement”) is entered into as of October 13, 2014 (the “Effective Date”) by and between Allergen Research Corporation, a California corporation, having its principal place of business at 2000 Alameda de las Pulgas, Suite 161, San Mateo, California 94403 (“ARC”) and the Golden Peanut Company, LLC, a Georgia corporation, having its principal place of business at 100 North Point Center East, Suite 400, Alpharetta, Georgia 30022 (together with its Affiliates and subsidiaries, collectively “Supplier”). ARC and Supplier are referred to collectively as the “Parties” and individually as a “Party”.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 6th, 2015 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Amended and Restated Investors’ Rights Agreement is made as of January 20, 2015 (the “Effective Date”) by and among Allergen Research Corporation, a Delaware corporation (the “Company”), each of the investors listed on Annex A attached hereto, each of which is referred to in this Agreement as an “Investor” and any additional Investor (as defined in the Purchase Agreement, as hereinafter defined) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION LEASEAimmune Therapeutics, Inc. • July 6th, 2015 • Pharmaceutical preparations • Florida
THIS LEASE, made and entered into this 8th day of June, 2015, by and between MID A GROUP, LLC, a Florida limited liability company (hereinafter ‘the “Landlord”) and ALLERGEN RESEARCH CORPORATION, a California corporation (hereinafter the ‘Tenant”),
CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION CONSULTING AGREEMENTConsulting Agreement • July 6th, 2015 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations
This Agreement is made and entered into as of February 9, 2015 (“Effective Date”) by and between Allergen Research Corporation (“Company”), having a principal place of business at 2000 Alameda de las Pulgas, Suite 161, San Mateo, CA 94403 and Bryan L. Walser, (“Consultant”) having a principal place of business at [***].
